Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of cell therapy pioneer Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther brings more than 30 years of experience translating regenerative medicine innovations from development to clinical application. Dr. Günther

MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Statistically Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence

Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...

Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...

MUVON clears phase 2 interim milestone and announces participation in 2025 J.P. Morgan Healthcare Conference

MUVON Therapeutics announces the appointment of Dorothea Ledergerber, PhD, and Christoph Herwig, PhD to its Advisory Board.

Zurich, Switzerland, September 25, 2023 – MUVON Therapeutics, a leading Swiss biotech startup, is advancing a minimally-invasive personalized tissue-engineered regenerative therapy for female urinary incontinence. During Urology Week (24-30 September), MUVON Therapeutics joins the European Association of Urology (EAU) and supports their Urge to Act campaign focused on making policymakers aware that there are novel approaches under investigation to improve continence health

First in Human (FIH) trial results of MUVON's regenerative therapy for the treatment of stress urinary incontinence are now officially published in the International Urogynecology Journal. Deana Mohr, CEO: “We are thrilled with peer-review publication of our first-in-human phase I clinical trial demonstrating that the implantation of autologous muscle precursor cells for the treatment of Stress Urinary Incontinence in women is safe and feasible.” John F Coelho, Medical

Zurich, Switzerland, November 16, 2022 – MUVON Therapeutics announces the appointment of Dr Branimir Brankov to its Board of Directors...

Zurich, Switzerland, October 27, 2022 – Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that...

Zurich, Switzerland, September 8, 2022 -- Muvon Therapeutics AG, an innovative clinical-stage biotechnology company announced results...

Today, the World Federation of Incontinence and Pelvic Problems (WFIPP) released a statement of partnership and collaboration with award-winning MUVON Therapeutics AG exponentially enhancing global awareness and knowledge on novel experimental breakthrough treatment options for stress-urinary incontinence though an educational program. Mary Lynne van Poelgeest-Pomfret, the President of WFIPP and Deana Mohr, CEO of MUVON Therapeutics share a unified vision to create a world wh

MUVON Therapeutics is proud to have been selected as one of 30 start-ups and projects from around the world to join Switzerlands first...

MUVON Therapeutics is proud to announce the acceptance as a Wyss Zurich Project starting April 2021. The Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well

In October 2020 MUVON Therapeutics Ltd. was founded. The technology behind MUVON was developed over the past decade at the University of...